Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer

Reuters01-22

Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008). Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122359919) on January 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605994524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605994524","market":"nz","top_or_hot":-1,"title":"Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008). Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122359919) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008). Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122359919) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2Km0S0:1","article_id":"2605994524","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605994524","pubTimestamp":1769086895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression . Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","CORT":"Corcept医疗"},"translate_title":"Corcept Therapeutics报告Relacorilant治疗铂类耐药卵巢癌的3期ROSELLA试验取得成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer\n    \n\n        Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008). Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122359919) on January 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605994524","isCrawlerRequest":true}